The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1470
ISSUE1470
June 8, 2015
Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC
June 8, 2015 (Issue: 1470)
The FDA has approved nivolumab (Opdivo – BMS),
an IV programmed death receptor-1 (PD-1) blocking
antibody, for treatment of unresectable or metastatic
melanoma that has progressed following treatment
with ipilimumab (and a BRAF inhibitor in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.